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Abstract
Background: Results from external quality assessment 
schemes (EQASs) can provide information about accuracy 
and comparability of different measurement methods, 
provided that the material used in these schemes behave 
identical to patient samples among the different methods, 
a characteristic also known as commutability. The aim of 
this study was to assess the commutability of different 
matrices for the material used in an EQAS for tobramycin.
Methods: Proficiency testing material (PTM) and patient 
samples containing tobramycin were prepared, collected, 
pooled, and distributed to participating laboratories for 
analysis. Low, medium, and high tobramycin concen-
trations in liquid human, liquid bovine and lyophilized 
bovine serum were tested in this study. The patient serum 
results of every laboratory were plotted against each of the 
other laboratories, and the distances of the PTM results 
to the patient serum regression line were calculated. For 
comparison, these distances were divided by the average 
within-laboratory standard deviation (SDwl) of the results 
reported in the official EQAS for tobramycin, resulting in 
a relative residual. The commutability decision limit was 
set at 3 SDwl.
Results: With 10 laboratories participating in this study, 
45 laboratory couples were formed. For human serum, 
only one relative residual for high concentrations of 
tobramycin was found outside the commutability deci-
sion limit. For liquid and lyophilized bovine sera, the 
number of relative residuals outside the decision limit was 
between 15 and 18 for low, medium, and high tobramycin 
concentrations.
Conclusions: The PTM used for tobramycin is preferably 
prepared with human serum.
Keywords: commutability; external quality assessment 
scheme; immunoassay; proficiency testing.
Introduction
Results from external quality assessment schemes (EQASs) 
can serve multiple purposes [1]. Foremost, the participat-
ing individual laboratory can compare its own results to the 
target value and/or to the results of the other participating 
laboratories, indicating good, acceptable, or poor perfor-
mance in that particular analysis. A second outcome of the 
results of EQAS is the information about the accuracy and 
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comparability of different measurement methods. Every 
medical laboratory is obliged to perform in these inter-
laboratory comparisons, according to the International 
Organization for Standardization (ISO) standard 15189 [2].
For genuine comparison of results within and 
between laboratories and methods, the samples used 
in EQAS preferably behave identical to patient samples 
among the different methods of analysis used [3–6]. This 
characteristic is called commutability and is defined by 
the Clinical and Laboratory Standards Institute (CLSI) 
as “the ability of a material to yield the same numerical 
relationships between results of measurements by a given 
set of measurement procedures, purporting to measure 
the same quantity, as those between the expectations of 
the relationships obtained when the same procedures are 
applied to other relevant types of material” [7].
After commutability has been established for a mate-
rial used in EQAS, the unbiased comparison of results 
between laboratories and methods can reveal the varia-
tion among methods and serve as a starting point for har-
monization [8], which is of particular importance given 
the fact that hospitals specialize in different treatments 
and patients visit more than one hospital. With harmoni-
zation, patient care can be improved, clinical guidelines 
can be better applied, and the amount of medical errors 
and healthcare costs can be decreased [8].
The Dutch EQAS organizer, the Dutch Foundation for 
Quality Assessment in Medical Laboratories (SKML), pro-
vides inter-laboratory comparisons which cover the entire 
field of medical laboratories. The Association for Quality 
Assessment in Therapeutic Drug Monitoring and Clinical 
Toxicology (KKGT), is a section of SKML and provides the 
inter-laboratory comparisons in the field of therapeutic 
drug monitoring and clinical toxicology. This commuta-
bility study is the second commutability study performed 
by KKGT and is part of the Dutch project “Calibration 
2.000” [9]. The first study examined the commutability of 
the sample for analysis of anti-epileptic drugs [10]. Car-
bamazepine and valproic acid were chosen to represent 
the sample containing a total of nine anti-epileptic drugs. 




The study design of this commutability evaluation study is compa-
rable to the design of the commutability evaluation of proficiency 
testing material (PTM) for carbamazepine and valproic acid [10]. 
In this previous commutability study with carbamazepine and valp-
roic acid, in which carbamazepine and valproic acid were the least 
and the most robust process, respectively, no difference in commut-
ability could be demonstrated between the most and least robust 
 process [10].
In the antibiotic drugs PTM, tobramycin was the least robust 
proficiency testing (PT) process according to the retrospective data 
analysis of the averages of results reported by all participants over a 
period of 10 years. The process capability index (Cpk) [11] values were 
0.24, 0.32, 0.37, 0.17, and 0.63 for amikacin, gentamicin, methotrexate, 
tobramycin, and vancomycin, respectively. Since no difference in com-
mutability could be demonstrated in the aforementioned carbamaz-
epine and valproic acid study [10] between the most and least robust 
process, only tobramycin was chosen to be tested in this study because 
we assume that tobramycin is the most prone to non-commutability 
since the results of the analysis in our EQAS is the least robust.
Candidate matrices
In this commutability study, two different origins of matrices are 
tested, human and bovine serum. The samples are preferably distrib-
uted to the participants by mail, therefore the effect of lyophilization 
of bovine serum on commutability was also tested. A total of three 
candidate matrices are tested in this study: frozen liquid human 
serum, frozen liquid bovine serum, and lyophilized bovine serum.
Blank bovine serum was purchased from Invitrogen (Paisley, 
Scotland, UK, www.invitrogen.com) in 500-mL bottles of gamma 
irradiated newborn calf serum. This serum was stored at –20 °C and 
slowly defrosted overnight at room temperature before sample prep-
aration. Blank human serum was obtained from healthy adults who 
participated in a hepatitis screening program in the first-line treat-
ment. The sera of approximately 70 healthy adults were collected in 
laboratory tubes and stored at –20 °C within 1 month before sample 
preparation and were defrosted at room temperature for 2 h before 
pooling. Pooling was performed on an open laboratory bench, where 
no protection for bacterial exposure was used and materials were not 
filtered before dispensing. The serum pool was tested for the pres-
ence of tobramycin and other drugs, and the presence of  HIV-1/2 anti-
bodies, hepatitis B surface antigen, and hepatitis C virus antibody. 
All test results were negative.
Both blank matrices were used for preparation of the candidate 
matrices samples.
Candidate matrices sample preparation
The blank candidate matrix samples were prepared by adding a volu-
metric quantity of a tobramycin stock solution in water to both matri-
ces. 110 mL blank bovine serum was spiked with 2.0, 4.0, and 6.0 mL 
of a tobramycin stock solution, and 5.00 mL blank human serum was 
spiked with 100, 165, and 265 μL tobramycin stock solution, to obtain 
low, medium, and high concentrations tobramycin (see Table  1). 
Matrices were stirred for 10 min, according to the local preparation 
protocol for EQAS material. The bovine serum was dispensed in vials 
in 2-mL aliquots, and half of the batch was lyophilized. The human 
serum was dispensed in laboratory vials in 250-μL aliquots. Both 
Brought to you by | University of Groningen
Authenticated
Download Date | 5/23/17 2:17 PM
214      Robijns et al.: Commutability evaluation
Table 1: Tobramycin concentrations (in mg/L) in candidate matrices 
samples.
  Human serum 
(liquid)
  Bovine serum 
(liquid)
  Bovine serum 
(lyophilized)
Low   2.9   2.7   2.6
Medium   4.8   5.4   5.2
High   7.5   8.2   7.8
liquid bovine serum and liquid human serum samples were stored 
at –20 °C and lyophilized bovine serum samples were stored in the 
refrigerator prior to dispatch.
Patient material preparation
Patient serum samples containing tobramycin left over from clinical 
analysis were collected during 3 months prior to the study. Hemolytic 
and icteric samples were rejected, no criteria for lipemic samples 
were defined. Samples were stored at –80 °C and defrosted at room 
temperature for 1 h prior to pool preparation. Pooling was performed 
on an open laboratory bench, where no protection for bacterial expo-
sure was used and materials were not filtered before dispensing. 
After pool preparation and partition in aliquots, the samples were 
stored at –20 °C prior to dispatch.
Six pool sera, including one blank serum, were prepared from 
the leftover patient serum samples, resulting in tobramycin concen-
trations covering the range normally covered by immunoassays. The 
tobramycin concentrations of the pool sera were 1.8, 3.8, 5.5, 8.0, and 
9.3 mg/L, determined as the mean value of the results reported by the 
laboratories participating in this commutability study.
Participants and measurement methods
Participants of the Dutch antibiotic drugs EQAS were asked to per-
form in this commutability study. Among the participants, a selec-
tion was made according to the immunoassay in use, to include every 
immunoassay currently used for the analysis of tobramycin.
Written instructions about dispatch, storage condition, recon-
stitution of the lyophilized samples, and minimum/maximum time 
between samples receipt and analysis were send to the participating 
laboratories. All materials were send on dry ice and delivered within 
24 h to the laboratories. Participants were instructed to analyze the 
samples on the day of receipt or within 24 h. Liquid samples which 
were received in a frozen state could be stored at –20 °C prior to anal-
ysis, but needed to be analyzed within 24 h. Frozen samples were 
thawed at room temperature. Liquid samples which were thawed at 
arrival needed to be analyzed immediately or stored in the refrigera-
tor and analyzed within 24 h. Participants were instructed to homog-
enize the thawed liquid samples, a vortex could be used. Lyophilized 
samples needed to be restored in the refrigerator until reconstitution 
and analysis. Participants were instructed to reconstitute these sam-
ples by adding 2.00 mL of distilled water, leave the vial for 15 min 
on the workbench, and then carefully mix without shaking until dis-
solved completely. Every sample needed to be analyzed in duplicate 
in a single run to improve statistical power.
Ten laboratories participated in this commutability evalua-
tion. All laboratories used an immunoassay method for the analysis 
of tobramycin. One laboratory was not able to analyze the samples 
in duplicate, and a second laboratory stated no lyophilized bovine 
serum samples were received.
Five different immunoassay methods were used. Four labo-
ratories used the fluorescence polarization immunoassay (FPIA) 
method by Abbott, two used FPIA by Roche, two used cloned enzyme 
donor immunoassay (CEDIA) by Roche, one used enzyme multiplied 
immunoassay technique (EMIT) by Siemens, and one used parti-
cle-enhanced turbidimetric inhibition immunoassay (PETINIA) by 
Siemens. With 10 laboratories participating in this commutability 
evaluation, 45 laboratory couples could be formed with 13 different 
method comparisons (see Table 2).
Data analysis
Data analysis was performed comparable to the data analysis in the 
carbamazepine and valproic acid commutability evaluation [10]. 
CLSI guideline EP30-A [12] was applied for data analysis.
In brief, the results of every laboratory were compared to the 
results of each of the other laboratories. The mathematical rela-
tionships of the tobramycin results of the patient samples between 
the laboratories were compared to the mathematical relationships 
of the results of the candidate matrix samples (see Figure 1 for an 
example, see Supplemental Figure 1 for results from all 45 labora-
tory couples).
To express commutability, the orthogonal residuals between 
the results of the candidate matrix samples and the patient samples 
using Passing and Bablok regression are calculated and for compari-
son expressed as a multiple of the within-laboratory standard devia-
tion (SDwl). This SDwl is the average SDwl calculated from EQAS results 
for tobramycin over a period of 3 years. The commutability decision 
limit was set at 3 SDwl, which is a more robust, consistent, and mostly 
more stringent limit than two standard error of regression of each 
pair of laboratories.
Table 2: Number of laboratory couples for each method 
comparison.
Method 1   Method 2   Number of method 
comparisons
FPIA Abbott   FPIA Abbott   6
  FPIA Roche   8
  CEDIA Roche   8
  EMIT Siemens   4
  PETINIA Siemens  4
FPIA Roche   FPIA Roche   1
  CEDIA Roche   4
  EMIT Siemens   2
  PETINIA Siemens  2
CEDIA Roche   CEDIA Roche   1
  EMIT Siemens   2
  PETINIA Siemens  2
EMIT Siemens  PETINIA Siemens  1
Total     45
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Figure 2: Relative residuals for liquid human, liquid bovine and 
lyophilized bovine sera spiked with low (L), medium (M) and high (H) 
concentrations of tobramycin.
Commutability decision limit at 3 SDwl, indicated by dashed line 
(----).
Figure 1: Example of data analysis of two laboratories.
○, patient samples; ●, candidate matrix samples (A, B, or C); 
dashed line (----), patient sample regression line; continuous line 
(—), orthogonal residual.
Results
Calculated relative residuals are presented in Figure 2. The 
analysis of tobramycin in liquid human serum produced 
only one relative residual outside the commutability 
cut-off limit of 3 SDwl, for the highest concentration. This 
relative residual was produced by a combination of labo-
ratories which both used the FPIA method by Abbott. For 
the analysis of all other samples by these two laboratories, 
no relative residuals outside the commutability cut-off 
limit were produced.
For the liquid and lyophilized bovine serum samples, 
a large amount of relative residuals were outside the 
commutability cut-off value. For liquid bovine serum 
15, 15, and 11 relative residuals exceeded 3 SDwl, for low, 
medium, and high concentrations of tobramycin, respec-
tively. For lyophilized bovine serum these numbers were 
14, 12, and 12 for low, medium, and high concentrations, 
respectively.
Every laboratory couple with a CEDIA method by 
Roche produced relative residuals outside 3 SDwl for liquid 
and lyophilized bovine serum. The laboratory couple 
consisting of the two CEDIA methods by Roche did not 
produce relative residuals outside 3 SDwl for liquid and 
lyophilized bovine serum.
When an even more strict commutability decision 
limit of 2 SDwl had been chosen, the result remains the 
same. The number of relative residuals is the lowest in the 
liquid human serum samples and increases in both liquid 
and lyophilized bovine serum samples (see Table 3).
Discussion
The current commutability study is designed comparable 
to the previous carbamazepine and valproic acid commut-
ability study [10]. Due to an expensive and time-consum-
ing commutability assessment method described in CLSI 
EP30-A guideline [12], both studies were designed as an 
X-ling design, in which every laboratory is coupled with 
each of the other laboratories, thereby creating multiple 
method comparisons. Because of this design, every labo-
ratory needed to receive the same sera; therefore, large 
amounts of patient sera in different concentrations were 
required, for which patient sera were pooled. According 
to CLSI EP30-A, the commutability of this pooled serum 
needs to be examined, which is even more work than 
this commutability study. Therefore, a small experiment 
was conducted to assess the deviation of the measured 
tobramycin concentration in the pool vs. the calculated 
tobramycin concentrations on the basis of the individual 
tobramycin concentrations. The deviations were 10%, 2%, 
–4%, 5%, and –2% for the respective pooled patient mate-
rials from the lowest to the highest concentration.
This pooling of sera can be an advantage due to dilut-
ing interfering substances, which can confound results of 
the commutability study, but can also be a disadvantage 
if one of the patient samples contains an interfering sub-
stance which contaminates the entire, thereby confound-
ing the results. In this commutability study, approximately 
10 patient sera were used for preparation of each of the 
serum pools; therefore, a potential interfering substance 
will probably be adequately diluted.
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Human serum (liquid)   
 
Bovine serum (liquid)   
 
Bovine serum (lyophilized) 
2 SDwl   3 SDwl 2 SDwl   3 SDwl 2 SDwl   3 SDwl
Tobramycin  Low   2   0   18   15   15   14
  Medium   2   0   17   15   15   12
  High   5   1   18   11   15   12
This pooling could be indicated as a shortcoming of 
the commutability study because preferably only individ-
ual patient sera including interfering substances would be 
used to represent the patient sample population. On the 
other hand, in an EQAS, the used samples will primarily 
be serum samples without interfering substances, to rep-
resent the majority of the patient sample population.
Results from this study indicate that material made 
with human serum behaves more like patient samples 
compared to bovine serum (both liquid and lyophilized), 
indicating that PTM is preferably prepared with human 
serum.
All relative residuals outside 3 SDwl for the analysis 
of tobramycin in liquid and lyophilized bovine serum 
samples were produced by every laboratory couple con-
taining one CEDIA method by Roche. Relative residuals 
produced by the combination of two laboratories who 
both use the CEDIA method were 2.17, 2.32, and 1.54 for 
low, medium, and high concentrations of tobramycin, 
respectively in liquid bovine serum, and 2.39, 2.45, and 
1.17 for low, medium, and high concentrations of tobramy-
cin, respectively, in lyophilized bovine serum. In human 
serum, no relative residuals for low, medium, and high 
tobramycin concentrations exceeded 3 SDwl and only 
one relative residual exceeded 2 SDwl (2.05) for laboratory 
couples containing one CEDIA method, indicating the 
CEDIA method is sensitive for components in the bovine 
serum matrices. This CEDIA method is no longer available 
for the analysis of tobramycin.
The one relative residual for human serum outside the 
commutability cut-off value of 3 SDwl is produced by two 
laboratories who both use the Abbott FPIA method. Other 
laboratory couples with a combination of two Abbott FPIA 
methods produced relative residuals for the highest con-
centration of tobramycin in human serum of 0.88, 1.61, 
1.74, 2.67, and 2.50 SDwl. All but one of the nine relative 
residuals outside 2 SDwl in human serum were produced 
by laboratory couples of which at least one of the labo-
ratories used the FPIA method by Abbott. This indicates 
that the candidate human serum sample might poten-
tially be unsuitable for the analysis of high concentrations 
of tobramycin. The FPIA method of Abbott is no longer 
available.
The relative residuals outside 3 SDwl in the carba-
mazepine commutability study might be the result of 
cross-reactivity of the carbamazepine-epoxide metabo-
lite in the immunoassays, but this cross-reactivity cannot 
explain the deviating relative residual for tobramycin in 
human serum since tobramycin is excreted unchanged 
[13]. Evaluation studies regarding the comparability 
between different immunoassays show significantly dif-
ferent results between methods [14, 15]. This possibly 
contributes to the relative residuals outside commutabil-
ity decision limit.
A shortcoming of this study is the absence of a tobramy-
cin sample in lyophilized human serum. Due to shipment of 
the samples in EQAS with regular mail, a lyophilized sample 
is preferred for transportation. However, a lyophilized 
sample has to be reconstituted, which carries an additional 
variability and patient samples are not lyophilized. Even 
though relative residuals for liquid and lyophilized bovine 
serum are comparable, these results cannot be extrapolated 
from liquid to lyophilized human serum.
Conclusions
Even though not all relative residuals for the analysis of 
tobramycin in human serum are below the commutability 
cut off limit of 3 SDwl, human serum is the preferred matrix 
for tobramycin in external quality assessment.
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